Renoprotection and renin-angiotensin system blockade in diabetes mellitus

American Journal of Hypertension

Volumn 10, Issue 12 II SUPPL., 1997, Pages

  Ruilope, Luis M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Angiotensin II receptor antagonist; Calcium channel blocker; Diabetic nephropathy; Hypertension; Irbesartan; Renal impairment

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; IRBESARTAN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0031427372     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00390-7     Document Type: Article

References (68)

1. U.S. renal data system, USRDS 1995 annual data report. National Institute of Health, Bethesda, MD, 1995.
2. Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin-dependent diabetes mellitus. Ann Intern Med. 111:1989;788-796.
3. Hirschl MM, Heinz G, Sunder-Plassmann G, Derfler K. Renal replacement therapy in type 2 diabetic patients 10 years' experience . Am J Kidney Dis. 10:1992;564-568.
4. Ravid M, Savin H, Lang R, et al. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. Arch Intern Med. 152:1992;1225-1229.
5. Disney APS: Sixteenth report of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). The Queen Elizabeth Hospital, Woodville, Australia, 1996.
6. Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 321:1989;1074-1079.
7. Pugh JA, Stern MP, Haffner SM, et al. Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am J Epidemiol. 127:1988;135-144.
8. Newman JM, Marfin AA, Eggers PW, Helgerson SD. End stage renal disease among native Americans, 1983-86. Am J Public Health. 80:1990;318-319.
9. Nelson RG, Newman JM, Knowler WC, et al. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 31:1988;730-736.
10. Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH. Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int. 35:1989;681-687.
11. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 33:1990;438-443.
12. Ballard DJ, Humphrey LL, Melton LJ III, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus population-based study in Rochester, Minnesota . Diabetes. 37:1988;405-412.
13. Parving H-H, Gall M-A, Skøtt P, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 41:1992;758-762.
14. Amoah E, Glickman JL, Malchoff CD, et al. Clinical identification of nondiabetic renal disease in diabetic patients with type I and type II diabetes presenting with renal dysfunction. Am J Nephrol. 8:1988;204-211.
15. Fabre J, Balant LP, Dayer PG, et al. The kidney in maturity onset diabetes mellitus a clinical study of 510 patients . Kidney Int. 21:1982;730-738.
16. Suzuki Y, Ueno M, Hayashi H, et al. A light microscopic study of glomerulosclerosis in Japanese patients with noninsulin-dependent diabetes mellitus the relationship between clinical and histological features . Clin Nephrol. 42:1994;155-162.
17. Renal biopsies in 30 micro and macroalbuminuric type 2 patients. Heterogeneity of renal lesions. Heidelberg, Germany: European Diabetic Nephropathy Study Group; European Diabetic Nephropathy Study Group; 1995.
18. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 334:1996;939-945.
19. Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;1051-1056.
20. Mogensen CE. Early glomerular hyperfiltration in insulin-dependent diabetes and late nephropathy. Scand J Clin Lab Invest. 46:1984;201-206.
21. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 311:1984;89-93.
22. Schmitz A: Albuminuria and renal disease in NIDDM-patients, in Mogensen CE (eds): The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers, Boston, 1994, pp 15-26.
23. Gall M-A, Rossing P, Skøtt P, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 34:1991;655-661.
24. Savage S, Nagel NJ, Estacio RO, et al. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis. 25:1995;836-844.
25. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients Cross-sectional data from the population-based study "Diabetes Care in General Practice," Denmark . Diabetologia. 36:1993;1007-1016.
26. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;1064-1070.
27. Mattock MB, Morrish NJ, Viberti GC, et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 41:1992;736-741.
28. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes A 10-year follow-up study of 503 patients . Diabet Med. 5:1988;126-134.
29. Rutherford PA, Thomas TH, Taylor R, Wilkinson R. Nephropathy and changes in sodium-lithium countertransport kinetics in type 2 (non-insulin-dependent) diabetes mellitus. J Hum Hypertens. 8:1994;29-35.
30. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 310:1984;356-360.
31. Cooper ME, Frauman A, O'Brien RC, et al. Progression of proteinuria in type 1 and type 2 diabetes. Diabet Med. 5:1988;361-368.
32. John L, Sunder Rao PSS, Kanagasabapathy AS. Rate of progression of albuminuria in type II diabetes Five-year prospective study from South India . Diabetes Care. 17:1994;888-890.
33. Pugh JA, Medina R, Ramirez M. Comparison of the course to end-stage renal disease of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic nephropathy. Diabetologia. 36:1993;1094-1098.
34. Gall M-A, Nielsen FS, Smidt UM, Parving H-H. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 36:1993;1071-1078.
35. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy A prospective study . Am J Med. 74:1983;256-264.
36. Sawicki PT, Didjurgeit U, Mühlhauser I, et al. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 17:1994;126-131.
37. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant. 9:1994;1097-1102.
38. Evanoff G, Thompson C, Brown J, Weinman E. Prolonged dietary protein restriction in diabetic nephropathy. Arch Intern Med. 149:1989;1129-1133.
39. Evanoff GV, Thompson CS, Brown J, Weinman EJ. The effect of dietary protein restriction on the progression of diabetic nephropathy A 12-month follow-up . Arch Intern Med. 147:1987;492-495.
40. CPT-11: from DNA topology to clinical activity. Semin Oncol 1996;23(suppl 3)1-50.
41. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states Relationship to atherogenesis . Diabetes Care. 14:1991;839-855.
42. Nelson RG, Knowler WC, Pettitt DJ, et al. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care. 18:1995;182-187.
43. Urinary albumin excretion over 3 years in diet-treated type 2 (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia. 36:1993;1021-1029.
44. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J. 285:1982;685-688.
45. Parving H-H, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J. 294:1987;1443-1447.
46. Björck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J. 293:1986;471-474.
47. Walker WG, Hermann J, Murphy R, Patz A. Elevated blood pressure and angiotensin II are associated with accelerated loss of renal function in diabetic nephropathy. Trans Am Clin Climatol Assoc. 97:1985;94-104.
48. Mimran A, Ribstein J. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertens. 7:1994;73S-81S.
49. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J. 302:1991;210-216.
50. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 113:1990;987-988.
51. Remuzzi A, Benigni A, Malanchini B, et al. ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. Kidney Int. 47:1995;1319-1326.
52. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
53. Viberti G, Morgensen CE, Groop LC, Pauls JF. Effects of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 271:1994;275-279.
54. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II effect of ACE inhibitors . Kidney Int. 47:1995;907-910.
55. Ravid M, Savin H, Jutrin I. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 118:1993;577-581.
56. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists a new class of antihypertensive drugs . Arch Intern Med. 155:1995;1361-1368.
57. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists a new approach to blockade of the renin-angiotensin system . Am Heart J. 127:1994;1388-1401.
58. Eberhardt RT, Kevak RM, Kang PM, Frishman WH. Angiotensin II receptor blockade an innovative approach to cardiovascular pharmacotherapy . J Clin Pharmacol. 33:1993;1023-1038.
59. Sissmann J, Bouroudian M, Armagnac C, et al. Angiotensin II blockade in healthy volunteers tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) (abs) . J Hypertens. 12:1994;S92.
60. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 75:1995;793-795.
61. Dahlöf B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens. 8:1995;578-583.
62. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects (abs). Clin Pharmacol Ther. 61:1997;207.
63. Marino MR, Langenbacher KM, Raymond RH, et al: Pharmacokinetics and pharmacodynamics of irbesartan in subjects with hepatic cirrhosis. J Clin Pharmacol (in press).
64. Stumpe KO, Haworth D, Höglund C, et al: Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press (in press).
65. Larochelle P, Flack JM, Marbury TC, et al: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol (in press).
66. Pohl M, Cooper M, Ulrey J, et al. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria (abs). Am J Hypertens. 10:(4, part 2):1997;105A.
67. O'Donnell MP, Kasiske BL, Keane WF, Powell JR. The angiotensin II receptor antagonist irbesartan reduces blood pressure and glomerular injury in obese Zucker rats (abs). Am J Hypertens. 9:(4, part 2):1996;80A.
68. Mackenzie HS, Provoost AP, Troy JL, et al. Irbesartan prevents renal injury in uninephrectomized (UNX) fawn-hooded hypertensive rats (FHH) (abs). J Am Soc Nephrol. 6:1995;1022.